Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Arcutis Biotherapeutics is advancing in alopecia areata and atopic dermatitis with ZORYVE. Learn why ARQT stock offers growth ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg ...

Diflucan (fluconazole) is a prescription antifungal medication used to treat fungal infections. Some common side effects are ...

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

A receding hairline may be common — about two-thirds of men start losing their hair by age 35 — but that doesn’t make it any ...

Medically reviewed by Katlein Franca, MD Central centrifugal cicatricial alopecia (CCCA) is a type of hair loss that begins at the top of the head and gradually spreads downward. It is most common in ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...